Yuejia Pharmaceuticals

Yuejia Pharmaceuticals is a private pharmaceutical company with operations in both the United States and China. Its lead asset, YJ001, is a topical small molecule spray developed for diabetic peripheral neuropathic pain. Clinical studies have shown that topical application results in low systemic exposure and favorable safety/tolerability profiles. In patients with diabetic neuropathic pain, the drug demonstrated significant reduction in pain and improved sleep quality compared to placebo, without serious adverse events reported. The company appears to be focused on advancing this candidate through clinical development stages both domestically and internationally.